Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
NCT04795219
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. NAFLD is the most common liver disease in US adults and the second leading cause for liver transplantation in the US. The natural history of NAFLD in the general population has been well described, with those with non-alcoholic fatty liver (NAFL, or simple steatosis) destin... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: NAFLD, NAFLD-HIV, Hiv
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Register for Updates
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311
Recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Lung Cancer, NSCLC
Register for Updates
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542
Recruiting
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part 2 is now closed to accrual.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Virginia Cancer Specialists PC, Fairfax, Virginia
Conditions: Prostate Cancer
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/05/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Hydrocephalus
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: VCU Medical Center, Richmond, Virginia
Conditions: Intracerebral Hemorrhage
Register for Updates
Cast Art for Kids With Extremity Fractures
NCT06990555
Recruiting
The goal of this clinical trial is to compare casts with cast art versus those without art in children who sustain a fracture of the extremity. The main goals are: * Determine the difference in satisfaction as measured by the visual analog scale for satisfaction between patients treated in a cast with cast customization versus those in a cast with no cast art * Determine the difference in perceived pain scores between patients treated in a cast with cast customization versus those in a case wit... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
06/04/2025
Locations: Naval Medical Center Portsmouth, Portsmouth, Virginia
Conditions: Fractures, Bone
Register for Updates
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
NCT06589596
Recruiting
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 as monotherapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Next Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumor
Register for Updates
SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization
NCT06550024
Recruiting
An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
06/04/2025
Locations: IR Centers, Leesburg, Virginia
Conditions: Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Arthritis, Osteoarthritis
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470
Recruiting
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Biotheryx Investigative Site, Fairfax, Virginia
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005
Recruiting
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Richmond, Virginia
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates